Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

• Status: COMPLETED
• Trial end date: 2025-02-01

Summary

This study will be held in the clinical oncology department, Helwan University, and Police Hospital, aiming to compare the efficacy and safety of anti-CD30 (BV) + Doxorubicin, Vinblastine, and Dacarbazine (AVD) versus the standard of care Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) as frontline therapy in patients with advanced classical Hodgkin lymphoma.

• Phase: NA

Details

• Lead Sponsor: Helwan University
• Treatments: Bleomycin; Brentuximab Vedotin; Dacarbazine; Doxorubicin; Vinblastine